surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2024-14-1-60-68surgonco-917Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSПерспективы комплексного скрининга и терапии рака шейки маткиProspects for Comprehensive Screening and Treatment of Cervical Cancerhttps://orcid.org/0009-0002-2181-9245БеглярзадеС. А.BegliarzadeS. A.

Беглярзаде Сема Арзуман, аспирант, кафедра онкологии, радиологии и радиотерапии

Тюмень

Sema A. Begliarzade — Postgraduate Student, Department of Oncology, Radiology and Radiotherapy

Tyumen

   

semanagiyeva@yandex.ruhttps://orcid.org/0000-0003-2960-1259МухаметоваР. Р.MukhametovaR. R.

Мухаметова Регина Ринатовна — к.м.н., кафедра медицинской генетики и фундаментальной медицины,

Республика Башкортостан, Уфа

   

Regina R. Mukhametova — Cand. Sci. (Med.), Department of Medical Genetics and Basic Medicine

Ufa

https://orcid.org/0000-0002-2178-2289ЖаоБ.ZhaoB.

Боксиан Жао — отделение нейрохирургии

Харбин

Boxian Zhao — Neurosurgery Unit

Harbin

   

Тюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian FederationБашкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian FederationПервый аффилированный госпиталь Харбинского медицинского университетаКитайFirst Affiliated Hospital of Harbin Medical UniversityChina2024180420241416068Copyright © Беглярзаде С.А., Мухаметова Р.Р., Жао Б., 20242024Беглярзаде С.А., Мухаметова Р.Р., Жао Б.Begliarzade S.A., Mukhametova R.R., Zhao B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/917

Рак шейки матки, второй по распространенности среди злокачественных опухолей у женщин, оказывает серьезное воздействие, особенно в менее развитых странах. Это приводит не только к страданиям пациентов и их семей, но также вызывает социальные и глобальные последствия. Основной целью настоящего обзора является выделение важности предотвращения и лечения рака шейки матки, обозначение текущих проблем и вызовов, а также указание на перспективы улучшения ситуации. Проведенный обзор базируется на анализе доступных данных в сети Интернет относительно скрининга и терапии рака шейки матки в России (поисковый запрос по ключевым словам), а также на иностранных исследованиях, представленных в публикациях (поиск по ключевым словам в системе PubMed — https://pubmed.ncbi.nlm.nih.gov/). В рамках исследования рассматриваются экономические и медицинские условия различных стран, выявляя нюансы и вызовы в реализации программ скрининга. Несмотря на существенное снижение заболеваемости и смертности от рака шейки матки в развитых странах благодаря инициативам по скринингу и вакцинации, остальные регионы продолжают сталкиваться с рядом проблем. Основной акцент на вакцинации и комплексной стратегии подчеркивает необходимость согласованных усилий. Требуются дальнейшие усилия в борьбе с раком шейки матки. Несмотря на прогресс в отдельных регионах, система здравоохранения развивающихся стран, включая Россию, требует постоянного совершенствования методов скрининга и лечения, а также координации усилий.

Cervical cancer, the second most common malignancy in women, poses a serious problem, especially for less developed countries. This results in the suffering of patients and their families, as well as causing social and global consequences. The present review aims to highlight the importance of preventing and treating cervical cancer, outline current problems and challenges, and indicate prospects for improvement. To this end, we analyzed available online data on cervical cancer screening and treatment in Russia (keyword search) and abroad (keyword search in PubMed, http://pubmed. ncbi.nlm.nih.gov/). The study examines the economic and health conditions of various countries, identifying nuances and challenges in implementing screening programs. In spite of significant reductions in cervical cancer incidence and mortality in developed countries due to screening and vaccination initiatives, other regions are still faced with a number of problems. The focus on vaccination and a comprehensive strategy indicates the need for a concerted effort. Further efforts are required in the fight against cervical cancer. While progress has been made in some regions, the health care system of developing countries, including Russia, requires constant improvement of screening and treatment methods, as well as coordination of efforts.

рак шейки маткивирус папилломы человекавакцинацияскринингсанитарное просвещениемировая инициативаглобальное здравоохранениеcervical cancerhuman papillomavirusvaccinationscreeninghealth educationworld initiativeglobal health careReferencesBray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: 10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: 10.3322/caac.21492.Sankaranarayanan R., Anorlu R., Sangwa-Lugoma G., Denny L.A. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine. 2013;31(Suppl. 5):F47–52. DOI: 10.1016/j.vaccine.2012.06.066Sankaranarayanan R., Anorlu R., Sangwa-Lugoma G., Denny L.A. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine. 2013;31(Suppl. 5):F47–52. DOI: 10.1016/j.vaccine.2012.06.066Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. DOI: 10.1016/S2214-109X(19)30482-6Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. DOI: 10.1016/S2214-109X(19)30482-6Bruni L., Albero G., Rowley J., Alemany L., Arbyn M., Giuliano A.R., et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023;11(9):e1345–62. DOI: 10.1016/S2214-109X(23)00305-4Bruni L., Albero G., Rowley J., Alemany L., Arbyn M., Giuliano A.R., et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023;11(9):e1345–62. DOI: 10.1016/S2214-109X(23)00305-4Ismail S., Deeks S., National Advisory Committee on Immunization. Summary of the National Advisory Committee on Immunization’s Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. Can Commun Dis Rep. 2015;41(suppl. 3):11–3. DOI: 10.14745/ccdr.v41is3a03Ismail S., Deeks S., National Advisory Committee on Immunization. Summary of the National Advisory Committee on Immunization’s Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. Can Commun Dis Rep. 2015;41(suppl. 3):11–3. DOI: 10.14745/ccdr.v41is3a03Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44. DOI: 10.1016/S1473-3099(10)70225-5Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44. DOI: 10.1016/S1473-3099(10)70225-5Schiffman M., Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med. 2013;369(24):2324–31. DOI: 10.1056/NEJMcp1210379Schiffman M., Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med. 2013;369(24):2324–31. DOI: 10.1056/NEJMcp1210379Crosbie E.J., Einstein M.H., Franceschi S., Kitchener H.C. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99. DOI: 10.1016/S0140-6736(13)60022-7Crosbie E.J., Einstein M.H., Franceschi S., Kitchener H.C. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99. DOI: 10.1016/S0140-6736(13)60022-7Franco E.L., de Sanjosé S., Broker T.R., Stanley M.A., Chevarie-Davis M., Isidean S.D., et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine. 2012;30(Suppl. 5(05)):F175–82. DOI: 10.1016/j.vaccine.2012.06.092Franco E.L., de Sanjosé S., Broker T.R., Stanley M.A., Chevarie-Davis M., Isidean S.D., et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine. 2012;30(Suppl. 5(05)):F175–82. DOI: 10.1016/j.vaccine.2012.06.092Кравец А., Кузнецов В.В., Морхов К.Ю., Нечушкина В.М., Хохлова С.В. Клинические рекомендации по диагностике и лечению рака шейки матки. М., 2014.Kravets A., Kuznetsov V.V., Morkhov K.Yu., Nechushkina V.M., Khokhlova S.V. Clinical guidelines for diagnosis and management of cervical cancer. Мoscow; 2014 (In Russ.).Хохлова С.В., Коломиец Л.А., Кравец О.А., Морхов К.Ю., Нечушкина В.М., Новикова Е.Г. и др. Практические рекомендации по лекарственному лечению рака матки. Злокачественные опухоли. 2019;9(3S2):203–17. DOI: 10.18027/2224-5057-2019-9-3s2-203-217Khokhlova S.V., Kolomiets L.A., Kravets O.A., Morkhov K.Yu., Nechushkina V.M., Novikova E.G., et al. Practice guidelines for medical management of cervical cancer. Malignant tumours. 2019;9(3S2):203–17 (In Russ.). DOI: 10.18027 / 2224-5057-2019-9-3s2-203-217Краснопольский В.И., Логутова Л.С., Зароченцева Н.В., Белая Ю.М., Тамазян Г.В., Гридчик А.Л. и др. Результаты вакцинопрофилактики ВПЧ-ассоциированных заболеваний и рака шейки матки в Московской области. Российский вестник акушера-гинеколога. 2015;15(3):9–14. DOI: 10.17116/rosakush20151539-14Krasnopol’skiy V.I., Logutova L.S., Zarochentseva N.V., Belaia Iu.M., Tamazian G.V., Gridchik A.L., et al. Results of vaccination against HPV-related diseases and cervical cancer in the Moscow Region. Russian Bulletin of Obstetrician-Gynecologist. 2015;15(3):9–14 (In Russ.). DOI: 10.17116/rosakush20151539-14Дьяков И.А. Фармакоэкономическая эффективность квадривалентной вакцины для профилактики ВПЧассоциированных заболеваний. Медицинский Совет. 2016;19:103– 8. DOI: 10.21518/2079-701X-2016-19-103-108Dyakov I.A. Pharmacoeconomic efficiency of quadrivalent vaccine to prevent HPV-associated diseases. Meditsinskiy sovet = Medical Council. 2016;(19):103–8 (In Russ.). DOI: 10.21518/2079-701X-2016-19-103-108Meites E., Szilagyi P.G., Chesson H.W., Unger E.R., Romero J.R., Markowitz L.E. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR. Morb Mortal Wkly Rep. 2019;68(32):698–702. DOI: 10.15585/mmwr.mm6832a3Meites E., Szilagyi P.G., Chesson H.W., Unger E.R., Romero J.R., Markowitz L.E. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR. Morb Mortal Wkly Rep. 2019;68(32):698–702. DOI: 10.15585/mmwr.mm6832a3Brinkman J.A., Caffrey A.S., Muderspach L.I., Roman L.D., Kast W.M. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005;26(2):129–42. PMID: 15857016Brinkman J.A., Caffrey A.S., Muderspach L.I., Roman L.D., Kast W.M. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005;26(2):129–42. PMID: 15857016Odukoya O., Fox R.S., Hayman L.L., Penedo F.J. The International Society for Behavioral Medicine (ISBM) and the Society of Behavioral Medicine (SBM) advocate for the inclusion of behavioral scientists in the implementation of the Global Action Plan for the prevention of non-communicable diseases (NCDs) in low- and middle-income countries. Transl Behav Med. 2021;11(6):1286–8. DOI: 10.1093/tbm/ibaa128Odukoya O., Fox R.S., Hayman L.L., Penedo F.J. The International Society for Behavioral Medicine (ISBM) and the Society of Behavioral Medicine (SBM) advocate for the inclusion of behavioral scientists in the implementation of the Global Action Plan for the prevention of non-communicable diseases (NCDs) in low- and middle-income countries. Transl Behav Med. 2021;11(6):1286–8. DOI: 10.1093/tbm/ibaa128Garg P., Mohanty A., Ramisetty S., Kulkarni P., Horne D., Pisick E., et al. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189026. DOI: 10.1016/j.bbcan.2023.189026Garg P., Mohanty A., Ramisetty S., Kulkarni P., Horne D., Pisick E., et al. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189026. DOI: 10.1016/j.bbcan.2023.189026Jit M., Brisson M. Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. Int J Cancer. 2018;143(2):317–23. DOI: 10.1002/ijc.31321Jit M., Brisson M. Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. Int J Cancer. 2018;143(2):317–23. DOI: 10.1002/ijc.31321Marchetti R.L., Gallucci-Neto J., Kurcgant D., Proença I.C.G.F., Valiengo L.D.C.L., Fiore L.A. Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV vaccination in Rio Branco, Brazil. Vaccine. 2020;38(43):6714–20. DOI: 10.1016/j.vaccine.2020.08.044Marchetti R.L., Gallucci-Neto J., Kurcgant D., Proença I.C.G.F., Valiengo L.D.C.L., Fiore L.A. Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV vaccination in Rio Branco, Brazil. Vaccine. 2020;38(43):6714–20. DOI: 10.1016/j.vaccine.2020.08.044Plummer M., de Martel C., Vignat J., Ferlay J., Bray F., Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16. DOI: 10.1016/S2214-109X(16)30143-7Plummer M., de Martel C., Vignat J., Ferlay J., Bray F., Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16. DOI: 10.1016/S2214-109X(16)30143-7Ogilvie G., Nakisige C., Huh W.K., Mehrotra R., Franco E.L., Jeronimo J. Optimizing secondary prevention of cervical cancer: recent advances and future challenges. Int J Gynaecol Obstet. 2017;138(Suppl. 1):15–9. DOI: 10.1002/ijgo.12187Ogilvie G., Nakisige C., Huh W.K., Mehrotra R., Franco E.L., Jeronimo J. Optimizing secondary prevention of cervical cancer: recent advances and future challenges. Int J Gynaecol Obstet. 2017;138(Suppl. 1):15–9. DOI: 10.1002/ijgo.12187Bergman H., Buckley B.S., Villanueva G., Petkovic J., Garritty C., Lutje V. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD013479. DOI: 10.1002/14651858.CD013479Bergman H., Buckley B.S., Villanueva G., Petkovic J., Garritty C., Lutje V. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD013479. DOI: 10.1002/14651858.CD013479Mahumud R.A., Gow J., Alam K., Keramat S.A., Hossain M.G., Sultana M. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh. Vaccine. 2020;38(2):165–72. DOI: 10.1016/j.vaccine.2019.10.037Mahumud R.A., Gow J., Alam K., Keramat S.A., Hossain M.G., Sultana M. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh. Vaccine. 2020;38(2):165–72. DOI: 10.1016/j.vaccine.2019.10.037Tsu V.D., LaMontagne D.S., Atuhebwe P., Bloem P.N., Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects. Prev Med. 2021;144:106335. DOI: 10.1016/j.ypmed.2020.106335Tsu V.D., LaMontagne D.S., Atuhebwe P., Bloem P.N., Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects. Prev Med. 2021;144:106335. DOI: 10.1016/j.ypmed.2020.106335Simms K.T., Steinberg J., Caruana M., Smith M.A., Lew J.B., Soerjomataram I., et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394–407. DOI: 10.1016/S1470-2045(18)30836-2Simms K.T., Steinberg J., Caruana M., Smith M.A., Lew J.B., Soerjomataram I., et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394–407. DOI: 10.1016/S1470-2045(18)30836-2Brisson M., Kim J.J., Canfell K., Drolet M., Gingras G., Burger E.A. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–90. DOI: 10.1016/S0140-6736(20)30068-4Brisson M., Kim J.J., Canfell K., Drolet M., Gingras G., Burger E.A. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–90. DOI: 10.1016/S0140-6736(20)30068-4Poland G.A., Jacobson R.M. The clinician’s guide to the anti-vaccinationists’ galaxy. Hum Immunol. 2012;73(8):859–66. DOI: 10.1016/j.humimm.2012.03.014Poland G.A., Jacobson R.M. The clinician’s guide to the anti-vaccinationists’ galaxy. Hum Immunol. 2012;73(8):859–66. DOI: 10.1016/j.humimm.2012.03.014Brawley O.W., Cowal S.G. Civil society’s role in efforts to control women’s cancers. Lancet. 2017;389(10071):775–6. DOI: 10.1016/S0140-6736(16)31799-8Brawley O.W., Cowal S.G. Civil society’s role in efforts to control women’s cancers. Lancet. 2017;389(10071):775–6. DOI: 10.1016/S0140-6736(16)31799-8Small W. Jr, Bacon M.A., Bajaj A., Chuang L.T., Fisher B.J., Harkenrider M.M., et al. Cervical cancer: A global health crisis. Cancer. 2017;123(13):2404–12. DOI: 10.1002/cncr.30667Small W. Jr, Bacon M.A., Bajaj A., Chuang L.T., Fisher B.J., Harkenrider M.M., et al. Cervical cancer: A global health crisis. Cancer. 2017;123(13):2404–12. DOI: 10.1002/cncr.30667de Sanjose S., Brotons M., LaMontagne D.S., Bruni L. Human papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol. 2019;39:16–22. DOI: 10.1016/j.coviro.2019.06.006de Sanjose S., Brotons M., LaMontagne D.S., Bruni L. Human papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol. 2019;39:16–22. DOI: 10.1016/j.coviro.2019.06.006Ginsburg O. Global disparities in HPV vaccination. Lancet Glob Health. 2016;4(7):e428–9. DOI: 10.1016/S2214-109X(16)30107-3Ginsburg O. Global disparities in HPV vaccination. Lancet Glob Health. 2016;4(7):e428–9. DOI: 10.1016/S2214-109X(16)30107-3Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl. 5):F12–23. DOI: 10.1016/j.vaccine.2012.07.055Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl. 5):F12–23. DOI: 10.1016/j.vaccine.2012.07.055Garland S.M., Kjaer S.K., Muñoz N., Block S.L., Brown D.R., DiNubile M.J., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27. DOI: 10.1093/cid/ciw354Garland S.M., Kjaer S.K., Muñoz N., Block S.L., Brown D.R., DiNubile M.J., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27. DOI: 10.1093/cid/ciw354Egawa N., Egawa K., Griffin H., Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7(7):3863–90. DOI: 10.3390/v7072802Egawa N., Egawa K., Griffin H., Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7(7):3863–90. DOI: 10.3390/v7072802Mesher D., Soldan K., Howell-Jones R., Panwar K., Manyenga P., Jit M., et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32(1):26–32. DOI: 10.1016/j.vaccine.2013.10.085Mesher D., Soldan K., Howell-Jones R., Panwar K., Manyenga P., Jit M., et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32(1):26–32. DOI: 10.1016/j.vaccine.2013.10.085Abbas K.M., van Zandvoort K., Brisson M., Jit M. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. Lancet Glob Health. 2020;8(4):e536–44. DOI: 10.1016/S2214-109X(20)30022-XAbbas K.M., van Zandvoort K., Brisson M., Jit M. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. Lancet Glob Health. 2020;8(4):e536–44. DOI: 10.1016/S2214-109X(20)30022-XOlusola P., Banerjee H., Philley J., Dasgupta S. Human papilloma virusassociated cervical cancer and health disparities. Cells. 2019;8(6):622. DOI: 10.3390/cells8060622Olusola P., Banerjee H., Philley J., Dasgupta S. Human papilloma virusassociated cervical cancer and health disparities. Cells. 2019;8(6):622. DOI: 10.3390/cells8060622Yoshikawa H., Ebihara K., Tanaka Y., Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18–26 years. Cancer Sci. 2013;104(4):465–72. DOI: 10.1111/cas.12106Yoshikawa H., Ebihara K., Tanaka Y., Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18–26 years. Cancer Sci. 2013;104(4):465–72. DOI: 10.1111/cas.12106Apter D., Wheeler C.M., Paavonen J., Castellsagué X., Garland S.M., Skinner S.R., et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015;22(4):361–73. DOI: 10.1128/CVI.00591-14Apter D., Wheeler C.M., Paavonen J., Castellsagué X., Garland S.M., Skinner S.R., et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015;22(4):361–73. DOI: 10.1128/CVI.00591-14Barbaro B., Brotherton J.M. Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators. Aust N Z J Public Health. 2015;39(4):326–30. DOI: 10.1111/1753-6405.12372Barbaro B., Brotherton J.M. Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators. Aust N Z J Public Health. 2015;39(4):326–30. DOI: 10.1111/1753-6405.12372Arbyn M., Simon M., Peeters E., Xu L., Meijer C.J.L.M., Berkhof J., et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083–1095. DOI: 10.1016/j.cmi.2021.04.031Arbyn M., Simon M., Peeters E., Xu L., Meijer C.J.L.M., Berkhof J., et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083–1095. DOI: 10.1016/j.cmi.2021.04.031Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–206. DOI: 10.1016/S2214-109X(22)00501-0Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–206. DOI: 10.1016/S2214-109X(22)00501-0Brotherton J.M.L., Bloem P.N. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2018;47:42–58. DOI: 10.1016/j.bpobgyn.2017.08.010Brotherton J.M.L., Bloem P.N. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2018;47:42–58. DOI: 10.1016/j.bpobgyn.2017.08.010Zou Z., Fairley C.K., Ong J.J., Hocking J., Canfell K., Ma X., et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020;8(10):e1335–44. DOI: 10.1016/S2214-109X(20)30277-1Zou Z., Fairley C.K., Ong J.J., Hocking J., Canfell K., Ma X., et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020;8(10):e1335–44. DOI: 10.1016/S2214-109X(20)30277-1Petrosky E., Bocchini J.A. Jr, Hariri S., Chesson H., Curtis C.R., Saraiya M., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. Morb Mortal Wkly Rep. 2015;64(11):300–4. PMID: 25811679Petrosky E., Bocchini J.A. Jr, Hariri S., Chesson H., Curtis C.R., Saraiya M., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. Morb Mortal Wkly Rep. 2015;64(11):300–4. PMID: 25811679LaMontagne D.S., Barge S., Le N.T., Mugisha E., Penny M.E., Gandhi S., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821–30B. DOI: 10.2471/BLT.11.089862LaMontagne D.S., Barge S., Le N.T., Mugisha E., Penny M.E., Gandhi S., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821–30B. DOI: 10.2471/BLT.11.089862Canfell K., Caruana M., Gebski V., Darlington-Brown J., Heley S., Brotherton J., et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388. DOI: 10.1371/journal.pmed.1002388Canfell K., Caruana M., Gebski V., Darlington-Brown J., Heley S., Brotherton J., et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388. DOI: 10.1371/journal.pmed.1002388Cruickshank M.E., Pan J., Cotton S.C., Kavanagh K., Robertson C., Cuschieri K., et al. Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study. BJOG. 2017;124(9):1386–93. DOI: 10.1111/1471-0528.14562Cruickshank M.E., Pan J., Cotton S.C., Kavanagh K., Robertson C., Cuschieri K., et al. Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study. BJOG. 2017;124(9):1386–93. DOI: 10.1111/1471-0528.14562Rogovskaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Y., et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine. 2013;31(Suppl. 7):H46–58. DOI: 10.1016/j.vaccine.2013.06.043Rogovskaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Y., et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine. 2013;31(Suppl. 7):H46–58. DOI: 10.1016/j.vaccine.2013.06.043Whitworth H.S., Gallagher K.E., Howard N., Mounier-Jack S., Mbwanji G., Kreimer A.R. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine. 2020;38(6):1302–14. DOI: 10.1016/j.vaccine.2019.12.017Whitworth H.S., Gallagher K.E., Howard N., Mounier-Jack S., Mbwanji G., Kreimer A.R. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine. 2020;38(6):1302–14. DOI: 10.1016/j.vaccine.2019.12.017

The authors declare that there are no conflicts of interest present.